Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Dow
Citi
UBS
QuintilesIMS
Argus Health
AstraZeneca
Covington
US Army

Generated: August 22, 2017

DrugPatentWatch Database Preview

ADASUVE Drug Profile

« Back to Dashboard

Which patents cover Adasuve, and what generic Adasuve alternatives are available?

Adasuve is a drug marketed by Alexza Pharms and is included in one NDA. There are seventeen patents protecting this drug.

This drug has two hundred and fifteen patent family members in nineteen countries.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the loxapine profile page.

Summary for Tradename: ADASUVE

Patents:17
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list19
Clinical Trials: see list4
Patent Applications: see list2,940
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADASUVE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Alexza Pharms
ADASUVE
loxapine
POWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADASUVE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,008,615Delivery of anti-migraine compounds through an inhalation route► Subscribe
7,491,047Delivery of antihistamines through an inhalation route► Subscribe
6,776,978 Delivery of opioids through an inhalation route► Subscribe
9,308,208Aerosol generating method and device► Subscribe
7,645,442Rapid-heating drug delivery article and method of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADASUVE

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004104491► Subscribe
Japan4912566► Subscribe
Czech Republic20033223► Subscribe
Japan4510438► Subscribe
Canada2507158► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ADASUVE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00046Denmark► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
90040-2Sweden► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
3Finland► Subscribe
0609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
00609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Accenture
Federal Trade Commission
UBS
Boehringer Ingelheim
Fish and Richardson
US Army
Fuji
Healthtrust
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot